Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NAKHLE S SABA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1275714669
CMS profile
1297710
Location
BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$57,925.47

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NAKHLE S SABA

NPI 1275714669 · CMS profile ID 1297710

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275714669?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NAKHLE S SABA, NPI 1275714669, CMS profile ID 1297710. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275714669?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). NAKHLE S SABA, NPI 1275714669, CMS profile ID 1297710. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275714669?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
NAKHLE S SABA, NPI 1275714669, CMS profile ID 1297710, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1275714669?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $57,925.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharmacyclics LLC, An AbbVie Company $385.8001/29/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725688107 CMS
Pharmacyclics LLC, An AbbVie Company $154.8901/29/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725688111 CMS
Pharmacyclics LLC, An AbbVie Company $5.0001/29/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725688117 CMS
Pharmacyclics LLC, An AbbVie Company $487.4901/29/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725688121 CMS
Pharmacyclics LLC, An AbbVie Company $33.8301/29/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725688141 CMS
Pharmacyclics LLC, An AbbVie Company $31.2201/29/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725688145 CMS
Incyte Corporation $14.5601/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745794467 CMS
Janssen Biotech, Inc. $14.7501/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719326649 CMS
Pharmacyclics LLC, An AbbVie Company $3,800.0001/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687889 CMS
Pharmacyclics LLC, An AbbVie Company $176.4901/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687895 CMS
Pharmacyclics LLC, An AbbVie Company $27.2501/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687901 CMS
Pharmacyclics LLC, An AbbVie Company $2.8501/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687905 CMS
Pharmacyclics LLC, An AbbVie Company $324.6701/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725688037 CMS
Pharmacyclics LLC, An AbbVie Company $6.0001/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725688041 CMS
Pharmacyclics LLC, An AbbVie Company $389.9901/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725688045 CMS
Pharmacyclics LLC, An AbbVie Company $224.0001/10/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725688167 CMS
Pharmacyclics LLC, An AbbVie Company $20.4501/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687937 CMS
Pharmacyclics LLC, An AbbVie Company $17.8201/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687941 CMS
Pharmacyclics LLC, An AbbVie Company $3,800.0001/09/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687947 CMS
Pharmacyclics LLC, An AbbVie Company $189.2801/09/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687949 CMS
Pharmacyclics LLC, An AbbVie Company $15.1201/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687955 CMS
Pharmacyclics LLC, An AbbVie Company $4.1601/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687961 CMS
Pharmacyclics LLC, An AbbVie Company $311.5001/09/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687965 CMS
Pharmacyclics LLC, An AbbVie Company $316.9001/09/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687969 CMS
Pharmacyclics LLC, An AbbVie Company $201.0001/09/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687973 CMS
Pharmacyclics LLC, An AbbVie Company $493.4901/09/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687977 CMS
Pharmacyclics LLC, An AbbVie Company $26.4501/09/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687983 CMS
Pharmacyclics LLC, An AbbVie Company $52.0001/09/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725687986 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $116,344.19 202
PY2020 $57,925.47 78
PY2021 $59,492.76 55
PY2022 $187,661.80 203
PY2023 $133,171.87 159
PY2024 $182,636.87 212
PY2025 $104,798.01 144

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $50,085.00 12
PY2024 Recipient $1,232.74 2
PY2024 Principal investigator $199,296.45 22
PY2023 Principal investigator $541,315.58 62
PY2022 Recipient $40.00 1
PY2022 Principal investigator $379,003.27 47
PY2021 Principal investigator $171,422.95 48
PY2020 Principal investigator $146,109.61 28
PY2019 Principal investigator $115,093.98 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,300.00 12/01/2025 Covered Recipient Teaching Hospital
Tulane Medical Center
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) No dispute reported 06/30/2026 1240489635
Principal investigator 1 Incyte Corporation $2,380.00 12/01/2025 Covered Recipient Teaching Hospital
Tulane Medical Center
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) No dispute reported 06/30/2026 1240489641
Principal investigator 1 Eli Lilly and Company $3,520.05 10/22/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
STUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) (BRUIN CLL-321) No dispute reported 06/30/2026 1187892812
Principal investigator 1 Incyte Corporation $2,025.00 09/25/2025 Covered Recipient Teaching Hospital
Tulane Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1240489618
Principal investigator 1 Incyte Corporation $12,973.80 09/25/2025 Covered Recipient Teaching Hospital
Tulane Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1240489622
Principal investigator 1 Incyte Corporation $3,277.00 07/31/2025 Covered Recipient Teaching Hospital
Tulane Medical Center
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia. No dispute reported 06/30/2026 1240489628
Principal investigator 1 Incyte Corporation $374.40 07/24/2025 Covered Recipient Teaching Hospital
Tulane Medical Center
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib No dispute reported 06/30/2026 1240489612
Principal investigator 1 BeOne Medicines USA, Inc. $22,678.00 07/14/2025 Non-covered Recipient Entity
Tulane Cancer Center
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190332185
Principal investigator 1 Acerta Pharma LLC $247.50 05/28/2025 Non-covered Recipient Entity
TULANE UNIVERSITY SCHOOL OF MEDICINE
A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation No dispute reported 06/30/2026 1185553868
Principal investigator 1 KYOWA KIRIN, INC. $979.85 05/09/2025 Non-covered Recipient Entity
TULANE UNIVERSITY CANCER CENTER
OPEN-LABEL, PHASE 2 STUDY TO ASSESS THE SAFETY OF MOGAMULIZUMAB GIVEN EVERY 4 WEEKS FOLLOWING INDUCTION IN PARTICIPANTS WITH RELAPSED/REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL) No dispute reported 06/30/2026 1221805271
Principal investigator 1 Incyte Corporation $79.90 02/21/2025 Covered Recipient Teaching Hospital
Tulane Medical Center
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma No dispute reported 06/30/2026 1240489603
Principal investigator 1 Incyte Corporation $249.50 02/21/2025 Covered Recipient Teaching Hospital
Tulane Medical Center
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma No dispute reported 06/30/2026 1240489608